AI 共同創新中心
Novo Nordisk 與 AWS 部署其 AI 藥物研發中心
Novo Nordisk 與 Amazon Web Services 擴大合作範圍，於倫敦成立一個全新 AI 藥物研發中心，旨在加快藥物研發進程。這項計劃將 AWS 工程師、AI 專家及應用科學家，與 Novo Nordisk 的研發團隊結合，而 AWS 亦將成為公司在藥物研發領域的首選雲端服務供應商及策略性 AI 合作夥伴。
Novo Nordisk 將運用 Amazon Bio Discovery 及 Amazon Bedrock，分析基因組學、影像及臨床數據，識別潛在藥物標靶，並協助制定臨床試驗設計。公司亦將運用 Amazon Bedrock AgentCore，部署可自動化工作流程、提升營運效率的 AI 代理。AWS 亦將支援 Novo Nordisk 更廣泛技術基礎設施的現代化升級工作。
對研究人員而言，是次合作為運算及實驗室工作，打造一個更整合的環境。是次合作反映製藥業與雲端服務業之間的策略聯盟投資日益增加，旨在加快研究進度並提升藥物開發效率。
英文原文
Novo Nordisk and Amazon Web Services expanded their partnership with a new AI drug discovery hub in London designed to accelerate drug discovery. The initiative will bring AWS engineers, AI specialists and applied scientists together with Novo Nordisk research and development teams, while AWS becomes the company’s preferred cloud provider and strategic AI partner for drug discovery.
Novo Nordisk will use Amazon Bio Discovery and Amazon Bedrock to analyze genomic, imaging and clinical data, identify potential drug targets and help inform clinical trial design. The company will also use Amazon Bedrock AgentCore to deploy AI agents that automate workflows and improve operational efficiency. AWS will additionally support modernization of Novo Nordisk’s broader technology infrastructure.
For researchers, the collaboration creates a more integrated environment for computational and laboratory work. The partnership reflects growing investment in pharma-cloud alliances aimed at accelerating research and improving drug development efficiency.
- 來源
- Trend Hunter
- 發布
- 2026-08-21
- 品類
- Health
- 出處
- mobihealthnews, linkedin